Acquisitions and Divestitures - Narrative (Asset Acquisition) (Details) - USD ($) $ in Thousands, shares in Millions	Oct. 03, 2022	Aug. 17, 2022	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Common stock, $0.0001 par value (Note 12)			$ 199	$ 190
Intangibles estimated useful life			15 years
Developed Technology
Business Acquisition [Line Items]
Intangibles estimated useful life	5 years
Circularis Biotechnologies, Inc.
Business Acquisition [Line Items]
Business combination, change in amount of contingent consideration, asset	$ 18,600
Business combination, cash consideration transferred	4,300
Common stock, $0.0001 par value (Note 12)	3,700
Direct transaction costs	400
Employee retention payments	2,500
Circularis Biotechnologies, Inc. | Common Class A
Business Acquisition [Line Items]
Common stock, $0.0001 par value (Note 12)	$ 10,200
Baktus Inc
Business Acquisition [Line Items]
Business combination, change in amount of contingent consideration, asset		$ 11,100
Business combination, cash consideration transferred		2,000
Direct transaction costs		700
Employee retention payments		$ 1,000
Tax withholdings related to net share settlement of equity awards (in shares)		0.3
Vesting period (in months)		18 months
Payments to acquire intangible assets		$ 11,200
Deferred revenue		100
Baktus Inc | Common Class A
Business Acquisition [Line Items]
Common stock, $0.0001 par value (Note 12)		$ 8,400